Horses for Courses in the Era of CARs: Advancing CAR T and CAR NK Cell Therapies
The adoptive transfer of allogeneic CAR NK cells holds great promise as an anticancer modality due to the relative ease of manufacturing and genetic modification of NK cells, which translates into affordable pricing. Compared to the pronounced efficacy of CAR T cell therapy in the treatment of B cel...
Saved in:
Main Authors: | Sergey Kulemzin, Igor Evsyukov, Tatiana Belovezhets, Alexander Taranin, Andrey Gorchakov |
---|---|
Format: | article |
Language: | EN |
Published: |
MDPI AG
2021
|
Subjects: | |
Online Access: | https://doaj.org/article/a2b72c875ab4462e8f8d81b911b3bbf0 |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
The Race of CAR Therapies: CAR-NK Cells for Fighting B-Cell Hematological Cancers
by: Lara Herrera, et al.
Published: (2021) -
Current Perspectives on “Off-The-Shelf” Allogeneic NK and CAR-NK Cell Therapies
by: Erica L. Heipertz, et al.
Published: (2021) -
Armored CAR T-Cells: The Next Chapter in T-Cell Cancer Immunotherapy
by: Hawkins ER, et al.
Published: (2021) -
Cell Therapy for Colorectal Cancer: The Promise of Chimeric Antigen Receptor (CAR)-T Cells
by: Cristina Aparicio, et al.
Published: (2021) -
Engineered CAR-Macrophages as Adoptive Immunotherapies for Solid Tumors
by: Christopher Sloas, et al.
Published: (2021)